NASDAQ: OMGAOmega Therapeutics Inc Stock
$2.34-0.05 (-2.09%)
Updated Apr 23, 2024
OMGA Price
$2.34
Fair Value Price
N/A
Market Cap
$129.06M
52 Week Low
$1.30
52 Week High
$10.09
P/E
-1.3x
P/B
2.22x
P/S
52.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.09M
Earnings
-$97.43M
Gross Margin
100%
Operating Margin
-3,148.93%
Profit Margin
-3,148.9%
Debt to Equity
2.52
Operating Cash Flow
-$92M
Beta
1.78
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OMGA Overview
Omega Therapeutics, Inc. is developing a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. It has deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains. Omega Therapeutics was incorporated in 2016 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OMGA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OMGA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OMGA is good value based on its book value relative to its share price (2.22x), compared to the US Biotechnology industry average (5.93x)
P/B vs Industry Valuation
OMGA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OMGA due diligence checks available for Premium users.
Be the first to know about important OMGA news, forecast changes, insider trades & much more!
OMGA News
Valuation
OMGA fair value
Fair Value of OMGA stock based on Discounted Cash Flow (DCF)
Price
$2.34
Fair Value
$0.56
Overvalued by
316.16%
OMGA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OMGA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.3x
Industry
16.46x
Market
41.92x
OMGA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.22x
Industry
5.93x
OMGA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OMGA's financial health
Profit margin
Revenue
$989.0k
Net Income
-$20.2M
Profit Margin
-2,043.9%
OMGA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OMGA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$204.4M
Liabilities
$146.4M
Debt to equity
2.52
OMGA's short-term assets ($89.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OMGA's long-term liabilities ($119.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OMGA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.1M
Investing
$2.1M
Financing
$1.6M
OMGA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OMGA vs Biotech Stocks
Omega Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.